428 related articles for article (PubMed ID: 36745223)
21. Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma.
Nakajima S; Mimura K; Kaneta A; Saito K; Katagata M; Okayama H; Saito M; Saze Z; Watanabe Y; Hanayama H; Tada T; Sakamoto W; Momma T; Ohira H; Kono K
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):957-971. PubMed ID: 36368436
[TBL] [Abstract][Full Text] [Related]
22. Experimental evidence that carbon-ion radiotherapy utilizes cytotoxic T lymphocyte-mediated anti-tumor immunity for shrinking tumors compared to X-ray therapy.
Takeshima T; Hirayama R; Hasegawa S
Biochem Biophys Res Commun; 2024 Jul; 718():150058. PubMed ID: 38729076
[TBL] [Abstract][Full Text] [Related]
23. Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer.
Kaneta A; Nakajima S; Okayama H; Matsumoto T; Saito K; Kikuchi T; Endo E; Ito M; Mimura K; Kanke Y; Saito M; Saze Z; Fujita S; Sakamoto W; Onozawa H; Momma T; Ohki S; Kono K
Cancer Immunol Immunother; 2022 Nov; 71(11):2765-2776. PubMed ID: 35429245
[TBL] [Abstract][Full Text] [Related]
24. [Expression of the cGAS-STING Pathway in dMMR/MSI-H in Colorectal Cancer].
Kaneta A; Nakajima S; Mimura K; Kono K
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1130-1132. PubMed ID: 36281609
[TBL] [Abstract][Full Text] [Related]
25.
Si W; Liang H; Bugno J; Xu Q; Ding X; Yang K; Fu Y; Weichselbaum RR; Zhao X; Wang L
Gut; 2022 Mar; 71(3):521-533. PubMed ID: 33685966
[TBL] [Abstract][Full Text] [Related]
26. Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies.
Huang M; Cha Z; Liu R; Lin M; Gafoor NA; Kong T; Ge F; Chen W
Front Immunol; 2024; 15():1399926. PubMed ID: 38817608
[TBL] [Abstract][Full Text] [Related]
27. Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy.
Xing Y; Peng A; Yang J; Cheng Z; Yue Y; Liu F; Li F; Liu Y; Liu Q
Adv Sci (Weinh); 2024 Apr; 11(15):e2309583. PubMed ID: 38233164
[TBL] [Abstract][Full Text] [Related]
28. The role of cGAS-STING signalling in liver diseases.
Chen R; Du J; Zhu H; Ling Q
JHEP Rep; 2021 Oct; 3(5):100324. PubMed ID: 34381984
[TBL] [Abstract][Full Text] [Related]
29. cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity.
Pépin G; Gantier MP
Adv Exp Med Biol; 2017; 1024():175-194. PubMed ID: 28921470
[TBL] [Abstract][Full Text] [Related]
30. Ectopic expression of cGAS in
Waanders L; van der Donk LEH; Ates LS; Maaskant J; van Hamme JL; Eldering E; van Bruggen JAC; Rietveld JM; Bitter W; Geijtenbeek TBH; Kuijl CP
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072345
[TBL] [Abstract][Full Text] [Related]
31. A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy.
Li Q; Dong Z; Cao Z; Lei H; Wang C; Hao Y; Feng L; Liu Z
ACS Nano; 2023 Jun; 17(11):10496-10510. PubMed ID: 37184402
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Activation of cGAS for Cancer Immunotherapy.
Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
Front Immunol; 2021; 12():753472. PubMed ID: 34899704
[TBL] [Abstract][Full Text] [Related]
33. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
[TBL] [Abstract][Full Text] [Related]
34. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
[TBL] [Abstract][Full Text] [Related]
35. Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy.
Yang L; Wang Y; Song Y; Li Z; Lei L; Li H; He B; Cao J; Gao H
J Control Release; 2024 Jun; 370():354-366. PubMed ID: 38685387
[TBL] [Abstract][Full Text] [Related]
36. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
[TBL] [Abstract][Full Text] [Related]
37. GAS-STING: a classical DNA recognition pathways to tumor therapy.
Wang X; Lin M; Zhu L; Ye Z
Front Immunol; 2023; 14():1200245. PubMed ID: 37920470
[TBL] [Abstract][Full Text] [Related]
38. FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS-STING pathway activation.
Wu Y; Lin Y; Shen F; Huang R; Zhang Z; Zhou M; Fang Y; Shen J; Fan X
Neoplasia; 2024 Mar; 49():100973. PubMed ID: 38277817
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Tumor Cell-Intrinsic Expression of Cyclic GMP-AMP Synthase (cGAS)-Stimulator of Interferon Genes (STING) on the Infiltration of CD8
Nakajima S; Kaneta A; Okayama H; Saito K; Kikuchi T; Endo E; Matsumoto T; Fukai S; Sakuma M; Sato T; Mimura K; Saito M; Saze Z; Sakamoto W; Onozawa H; Momma T; Kono K
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345163
[TBL] [Abstract][Full Text] [Related]
40. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
Zhu C; Li J; Yao M; Fang C
BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
